

The role of the gut microbiota in NAFLD

Nature Reviews Gastroenterology and Hepatology
13, 412-425

DOI: [10.1038/nrgastro.2016.85](https://doi.org/10.1038/nrgastro.2016.85)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Microbiome and the Liver: The Basics. <i>Seminars in Liver Disease</i> , 2016, 36, 299-305.	1.8	13
2	The Metabolic Role of the Microbiome: Implications for NAFLD and the Metabolic Syndrome. <i>Seminars in Liver Disease</i> , 2016, 36, 312-316.	1.8	21
3	The Microbiome: What Will the Future Hold?. <i>Seminars in Liver Disease</i> , 2016, 36, 354-359.	1.8	4
5	Short chain fatty acids induce UCP2-mediated autophagy in hepatic cells. <i>Biochemical and Biophysical Research Communications</i> , 2016, 480, 461-467.	1.0	32
6	Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 211-223.	3.7	37
7	Clinical implications of understanding the association between oxidative stress and pediatric NAFLD. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 371-382.	1.4	37
8	Chemical signaling between gut microbiota and host chromatin: What is your gut really saying?. <i>Journal of Biological Chemistry</i> , 2017, 292, 8582-8593.	1.6	41
9	Current and future pharmacologic treatment of nonalcoholic steatohepatitis. <i>Current Opinion in Gastroenterology</i> , 2017, 33, 134-141.	1.0	43
10	Commensal bacteria (ab)use CD8 ⁺ T cells to induce insulin resistance. <i>Science Immunology</i> , 2017, 2, .	5.6	3
11	Frequency and Risk Factors of Clostridium difficile Infection in Hospitalized Patients With Pouchitis. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 661-671.	0.9	18
12	Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification. <i>Physiological Genomics</i> , 2017, 49, 385-399.	1.0	31
13	Infant nutrition and maternal obesity influence the risk of non-alcoholic fatty liver disease in adolescents. <i>Journal of Hepatology</i> , 2017, 67, 568-576.	1.8	92
14	Understanding the Molecular Mechanisms of the Interplay Between Herbal Medicines and Gut Microbiota. <i>Medicinal Research Reviews</i> , 2017, 37, 1140-1185.	5.0	241
15	CD40 signaling and hepatic steatosis: Unanticipated links. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017, 41, 357-369.	0.7	2
16	The interaction between smoking, alcohol and the gut microbiome. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 579-588.	1.0	144
17	Primary sclerosing cholangitis is protective against nonalcoholic fatty liver disease in inflammatory bowel disease. <i>Human Pathology</i> , 2017, 69, 55-62.	1.1	27
18	Preventing liver fibrosis in patients with NAFLD and the road ahead. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 1081-1083.	1.4	2
19	The relationship between non-alcoholic fatty liver disease and small intestinal bacterial overgrowth among overweight and obese children and adolescents. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2017, 30, 1161-1168.	0.4	36

#	ARTICLE	IF	CITATIONS
20	Cut-liver axis: gut microbiota in shaping hepatic innate immunity. <i>Science China Life Sciences</i> , 2017, 60, 1191-1196.	2.3	21
21	<i>Helicobacter pylori</i> infection and extragastric diseases in 2017. <i>Helicobacter</i> , 2017, 22, e12411.	1.6	47
22	NAFLD, <i>Helicobacter</i> species and the intestinal microbiome. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 657-668.	1.0	41
23	Editorial: new insights into the relationship between the intestine and nonalcoholic fatty liver—is fatty gut involved in disease progression?. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 377-378.	1.9	6
24	Managing nonalcoholic fatty liver disease in patients living with HIV. <i>Current Opinion in Infectious Diseases</i> , 2017, 30, 12-20.	1.3	15
25	Non-alcoholic Fatty Liver Disease in Non-obese Patients. <i>Current Hepatology Reports</i> , 2017, 16, 382-390.	0.4	0
26	The gut microbiome and liver cancer: mechanisms and clinical translation. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 527-539.	8.2	401
27	Mouse models of nonalcoholic steatohepatitis in preclinical drug development. <i>Drug Discovery Today</i> , 2017, 22, 1707-1718.	3.2	178
28	Multimorbidity and polypharmacy in diabetic patients with NAFLD. <i>Medicine (United States)</i> , 2017, 96, e6761.	0.4	39
29	Bad memories from the gut may cause nightmares for the bile ducts. <i>Journal of Hepatology</i> , 2017, 66, 5-7.	1.8	2
30	Role of Interleukin-22 in chronic liver injury. <i>Cytokine</i> , 2017, 98, 107-114.	1.4	25
31	Developmental origins of NAFLD: a womb with a clue. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 81-96.	8.2	162
33	Targeting the gut barrier for the treatment of alcoholic liver disease. <i>Liver Research</i> , 2017, 1, 197-207.	0.5	70
34	Systematic Review and Meta-Analysis: Prevalence of Small Intestinal Bacterial Overgrowth in Chronic Liver Disease. <i>Seminars in Liver Disease</i> , 2017, 37, 388-400.	1.8	55
35	The gut microbiome and nonalcoholic fatty liver disease. <i>Clinical Liver Disease</i> , 2017, 10, 116-119.	1.0	3
36	The Inhibitory Effects of Purple Sweet Potato Color on Hepatic Inflammation Is Associated with Restoration of NAD ⁺ Levels and Attenuation of NLRP3 Inflammasome Activation in High-Fat-Diet-Treated Mice. <i>Molecules</i> , 2017, 22, 1315.	1.7	39
37	Alpha-Galacto-Oligosaccharides at Low Dose Improve Liver Steatosis in a High-Fat Diet Mouse Model. <i>Molecules</i> , 2017, 22, 1725.	1.7	24
38	A Branched-Chain Amino Acid-Related Metabolic Signature Characterizes Obese Adolescents with Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2017, 9, 642.	1.7	92

#	ARTICLE	IF	CITATIONS
39	Short-Term Intake of a Fructose-, Fat- and Cholesterol-Rich Diet Causes Hepatic Steatosis in Mice: Effect of Antibiotic Treatment. <i>Nutrients</i> , 2017, 9, 1013.	1.7	41
40	Gut "Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease. <i>Children</i> , 2017, 4, 66.	0.6	85
41	Connection of Nicotine to Diet-Induced Obesity and Non-Alcoholic Fatty Liver Disease: Cellular and Mechanistic Insights. <i>Frontiers in Endocrinology</i> , 2017, 8, 23.	1.5	37
42	Gut Microbiota Modulation and Its Relationship with Obesity Using Prebiotic Fibers and Probiotics: A Review. <i>Frontiers in Microbiology</i> , 2017, 8, 563.	1.5	262
43	The Possible Role of <i>Helicobacter pylori</i> Infection in Non-alcoholic Fatty Liver Disease. <i>Frontiers in Microbiology</i> , 2017, 8, 743.	1.5	49
44	Prebiotic and Synbiotic Modifications of Beta Oxidation and Lipogenic Gene Expression after Experimental Hypercholesterolemia in Rat Liver. <i>Frontiers in Microbiology</i> , 2017, 8, 2010.	1.5	33
45	Human Gut Microbiota Associated with Obesity in Chinese Children and Adolescents. <i>BioMed Research International</i> , 2017, 2017, 1-8.	0.9	127
46	Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease. <i>Minerva Endocrinology</i> , 2017, 42, 184-194.	0.6	21
47	Non-Alcoholic Fatty Liver Disease: The Emerging Burden in Cardiometabolic and Renal Diseases. <i>Diabetes and Metabolism Journal</i> , 2017, 41, 430.	1.8	56
48	Current Trends and Future Prospective of Prebiotics as Therapeutic Food. , 2017, , 57-88.		9
49	Nonstructural 5A Protein of Hepatitis C Virus Interferes with Toll-Like Receptor Signaling and Suppresses the Interferon Response in Mouse Liver. <i>PLoS ONE</i> , 2017, 12, e0170461.	1.1	3
50	Signalling from the gut lumen. <i>Animal Production Science</i> , 2017, 57, 2175.	0.6	6
51	The Association of Inflammatory Markers With Nonalcoholic Fatty Liver Disease Differs by Human Immunodeficiency Virus Serostatus. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx153.	0.4	10
52	Nicotinamide adenine dinucleotide phosphate (reduced) oxidase 2 modulates inflammatory vigor during nonalcoholic fatty liver disease progression in mice. <i>Hepatology Communications</i> , 2018, 2, 546-560.	2.0	12
53	Tumor necrosis factor α -mediated hepatocyte apoptosis stimulates fibrosis in the steatotic liver in mice. <i>Hepatology Communications</i> , 2018, 2, 407-420.	2.0	27
54	Current State of Knowledge on Implications of Gut Microbiome for Surgical Conditions. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 1112-1123.	0.9	8
55	Improved Diet Quality Associates With Reduction in Liver Fat, Particularly in Individuals With High Genetic Risk Scores for Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2018, 155, 107-117.	0.6	127
56	An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans. <i>Cell Metabolism</i> , 2018, 27, 559-571.e5.	7.2	321

#	ARTICLE	IF	CITATIONS
57	Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. Annual Review of Pathology: Mechanisms of Disease, 2018, 13, 321-350.	9.6	387
58	Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance. Scientific Reports, 2018, 8, 1466.	1.6	196
59	Polysaccharide peptides from <i>Coriolus versicolor</i> : A multi-targeted approach for the protection or prevention of alcoholic liver disease. Journal of Functional Foods, 2018, 40, 769-777.	1.6	21
60	Microbiota and the liver. Liver Transplantation, 2018, 24, 539-550.	1.3	33
61	Microbial modulation of cardiovascular disease. Nature Reviews Microbiology, 2018, 16, 171-181.	13.6	301
62	Durability and Long-term Clinical Outcomes of Fecal Microbiota Transplant Treatment in Patients With Recurrent <i>Clostridium difficile</i> Infection. Clinical Infectious Diseases, 2018, 66, 1705-1711.	2.9	42
63	Metabonomic profiling of chronic intermittent hypoxia in a mouse model. Respiratory Physiology and Neurobiology, 2018, 256, 157-173.	0.7	19
64	Gut microbiota in adolescents and the association with fatty liver: the EPOCH study. Pediatric Research, 2018, 84, 219-227.	1.1	42
65	Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action. Molecular Aspects of Medicine, 2018, 64, 135-146.	2.7	103
66	Food additives, contaminants and other minor components: effects on human gut microbiota—a review. Journal of Physiology and Biochemistry, 2018, 74, 69-83.	1.3	127
67	Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut, 2018, 67, 534-541.	6.1	330
68	Immunoglobulin A and liver diseases. Journal of Gastroenterology, 2018, 53, 691-700.	2.3	38
69	Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: A prospective pilot study. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 369-384.	1.1	96
70	Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease. British Journal of Pharmacology, 2018, 175, 469-484.	2.7	116
71	Lipotoxicity and the gut-liver axis in NASH pathogenesis. Journal of Hepatology, 2018, 68, 280-295.	1.8	566
72	Gegen Qinlian Decoction Attenuates High-Fat Diet-Induced Steatohepatitis in Rats via Gut Microbiota. Evidence-based Complementary and Alternative Medicine, 2018, 2018, 1-8.	0.5	20
73	Small intestinal bacterial overgrowth (SIBO) and vitamin K-responsive coagulopathy: a previously unrecorded association. BMJ Case Reports, 2018, 2018, bcr-2017-223531.	0.2	3
74	Geniposide and Chlorogenic Acid Combination Ameliorates Non-alcoholic Steatohepatitis Involving the Protection on the Gut Barrier Function in Mouse Induced by High-Fat Diet. Frontiers in Pharmacology, 2018, 9, 1399.	1.6	60

#	ARTICLE	IF	CITATIONS
75	Intestinal Microbiota Modulation in Obesity-Related Non-alcoholic Fatty Liver Disease. <i>Frontiers in Physiology</i> , 2018, 9, 1813.	1.3	68
76	Vegetarian diet, food substitution, and nonalcoholic fatty liver. <i>Tzu Chi Medical Journal</i> , 2018, 30, 102.	0.4	22
77	Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms. <i>Endocrine Reviews</i> , 2018, 39, 629-663.	8.9	154
78	Proteome and microbiota analysis reveals alterations of liver-gut axis under different stocking density of Peking ducks. <i>PLoS ONE</i> , 2018, 13, e0198985.	1.1	15
79	Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota. <i>Frontiers of Medicine</i> , 2018, 12, 645-657.	1.5	28
80	A review of the pathogenic and therapeutic role of nutrition in pediatric nonalcoholic fatty liver disease. <i>Nutrition Research</i> , 2018, 58, 1-16.	1.3	29
81	Mechanisms of NAFLD development and therapeutic strategies. <i>Nature Medicine</i> , 2018, 24, 908-922.	15.2	2,392
82	Synthesis, Characterization of Inulin Propionate Ester, and Evaluation of its in Vitro Effect on SCFA Production. <i>Starch/Staerke</i> , 2018, 70, 1800037.	1.1	4
83	The Potential and Action Mechanism of Polyphenols in the Treatment of Liver Diseases. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-25.	1.9	80
84	Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2018, 87, 1-12.	1.5	80
85	Phytochemicals That Influence Gut Microbiota as Prophylactics and for the Treatment of Obesity and Inflammatory Diseases. <i>Mediators of Inflammation</i> , 2018, 2018, 1-18.	1.4	130
86	Mesenteric adipose tissue contributes to intestinal barrier integrity and protects against nonalcoholic fatty liver disease in mice. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, G659-G670.	1.6	22
87	The gut microbiota metabolite indole alleviates liver inflammation in mice. <i>FASEB Journal</i> , 2018, 32, 6681-6693.	0.2	137
88	Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis. <i>Nutrition Reviews</i> , 2018, 76, 822-839.	2.6	101
89	Fatty Liver Disease. , 2018, , 308-371.		14
90	Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-14.	1.9	447
91	Gut microbiota profiling in Han Chinese with type 1 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2018, 141, 256-263.	1.1	68
92	Unmet needs in pediatric NAFLD research: what do we need to prioritize for the future?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 961-967.	1.4	15

#	ARTICLE	IF	CITATIONS
93	Chrelin reduces TNF- α -induced human hepatocyte apoptosis, autophagy and pyroptosis: role in obesity-associated NAFLD. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 21-37.	1.8	67
94	Hepatic Steatosisâ€™a complex interaction of germs, genes and grub.. <i>Pediatric Research</i> , 2018, 84, 475-476.	1.1	0
95	Role of xenobiotics in the induction and progression of fatty liver disease. <i>Toxicology Research</i> , 2018, 7, 664-680.	0.9	22
96	Outside the liver box: The gut microbiota as pivotal modulator of liver diseases. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 912-919.	1.8	22
97	Role and effective therapeutic target of gut microbiota in NAFLD/NASH (Review). <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 1935-1944.	0.8	23
98	Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for nonâ€™alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 628-639.	1.9	39
99	Chitosan Oligosaccharide Ameliorates Nonalcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Mice. <i>Marine Drugs</i> , 2019, 17, 391.	2.2	43
100	Gut Microbiota Composition Is Associated With the Global DNA Methylation Pattern in Obesity. <i>Frontiers in Genetics</i> , 2019, 10, 613.	1.1	38
101	The combination of Ilexhainanoside D and ilexsaponin A1 reduces liver inflammation and improves intestinal barrier function in mice with high-fat diet-induced non-alcoholic fatty liver disease. <i>Phytomedicine</i> , 2019, 63, 153039.	2.3	19
102	Microbiota in Non-alcoholic Liver Disease. , 2019, , 103-111.		0
103	Diet Consisting of Balanced Yogurt, Fruit, and Vegetables Modifies the Gut Microbiota and Protects Mice against Nonalcoholic Fatty Liver Disease. <i>Molecular Nutrition and Food Research</i> , 2019, 63, e1900249.	1.5	19
104	Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5037.	1.8	98
105	The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. <i>Nutrients</i> , 2019, 11, 2642.	1.7	81
106	Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?. <i>Diseases (Basel, Switzerland)</i> , 2019, 7, 58.	1.0	84
107	Ratio of Conjugated Chenodeoxycholic to Muricholic Acids is Associated with Severity of Nonalcoholic Steatohepatitis. <i>Obesity</i> , 2019, 27, 2055-2066.	1.5	22
108	High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study. <i>BMJ Open Gastroenterology</i> , 2019, 6, e000315.	1.1	82
109	Relationship between Changes in Microbiota and Liver Steatosis Induced by High-Fat Feedingâ€™A Review of Rodent Models. <i>Nutrients</i> , 2019, 11, 2156.	1.7	30
110	Indole-3-propionic acid inhibits gut dysbiosis and endotoxin leakage to attenuate steatohepatitis in rats. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-14.	3.2	139

#	ARTICLE	IF	CITATIONS
111	Fatty Liver Disease Caused by High-Alcohol-Producing <i>Klebsiella pneumoniae</i> . <i>Cell Metabolism</i> , 2019, 30, 675-688.e7.	7.2	294
112	Pancreatic and mucosal enzymes in choline phospholipid digestion. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G425-G445.	1.6	35
113	Altered fecal bacterial composition correlates with disease activity in inflammatory bowel disease and the extent of IL8 induction. <i>Current Research in Translational Medicine</i> , 2019, 67, 41-50.	1.2	29
114	Mesenteric lymph node CD4+ T lymphocytes migrate to liver and contribute to non-alcoholic fatty liver disease. <i>Cellular Immunology</i> , 2019, 337, 33-41.	1.4	24
115	Interactions between the cecal microbiota and non-alcoholic steatohepatitis using laying hens as the model. <i>Poultry Science</i> , 2019, 98, 2509-2521.	1.5	37
116	Persistent changes in liver methylation and microbiome composition following reversal of diet-induced non-alcoholic-fatty liver disease. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 4341-4354.	2.4	32
117	Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. <i>American Journal of Clinical Nutrition</i> , 2019, 110, 139-149.	2.2	122
118	Efficacy of Probiotics and Synbiotics in Patients with Nonalcoholic Fatty Liver Disease: A Meta-Analysis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3402-3412.	1.1	68
119	Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway. <i>Free Radical Biology and Medicine</i> , 2019, 141, 192-204.	1.3	147
120	Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease. <i>Free Radical Biology and Medicine</i> , 2019, 144, 293-309.	1.3	146
121	Alcoholic/Non-Alcoholic Digestive Diseases. , 2019, , .		0
122	<i>Lactobacillus plantarum</i> NA136 improves the non-alcoholic fatty liver disease by modulating the AMPK/Nrf2 pathway. <i>Applied Microbiology and Biotechnology</i> , 2019, 103, 5843-5850.	1.7	65
123	Altered microbiomes distinguish Alzheimer's disease from amnesic mild cognitive impairment and health in a Chinese cohort. <i>Brain, Behavior, and Immunity</i> , 2019, 80, 633-643.	2.0	358
125	Probiotics: current landscape and future horizons. <i>Future Science OA</i> , 2019, 5, FSO391.	0.9	52
126	Hepatic MyD88 regulates liver inflammation by altering synthesis of oxysterols. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 317, E99-E108.	1.8	15
127	Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH). <i>Annals of Hepatology</i> , 2019, 18, 416-421.	0.6	49
128	Gastrointestinal and liver diseases and atrial fibrillation: a review of the literature. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481983223.	1.4	15
129	Functional Microbiomics in Liver Transplantation: Identifying Novel Targets for Improving Allograft Outcomes. <i>Transplantation</i> , 2019, 103, 668-678.	0.5	25

#	ARTICLE	IF	CITATIONS
130	Preventive Efficiency of Green Tea and Its Components on Nonalcoholic Fatty Liver Disease. <i>Journal of Agricultural and Food Chemistry</i> , 2019, 67, 5306-5317.	2.4	55
131	Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut-liver axis. <i>Proceedings of the Nutrition Society</i> , 2019, 78, 319-328.	0.4	84
132	Virtual Reality: New Insights Regarding the Prevalence of Nonalcoholic Fatty Liver Disease in Children and Adolescents with Obesity Using Magnetic Resonance Imaging. <i>Journal of Pediatrics</i> , 2019, 207, 8-10.	0.9	4
133	The long-term protective effects of neonatal administration of curcumin against nonalcoholic steatohepatitis in high-fructose-fed adolescent rats. <i>Physiological Reports</i> , 2019, 7, e14032.	0.7	7
134	Hepatitis B Virus, Hepatitis C Virus, the Microbiome, and Hepatocellular Carcinoma. , 2019, , 41-54.		0
135	Human Paneth cell Î±-defensin-5 treatment reverses dyslipidemia and improves glucoregulatory capacity in diet-induced obese mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 317, E42-E52.	1.8	22
136	Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation. <i>Journal of Internal Medicine</i> , 2019, 286, 32-40.	2.7	111
137	Characteristics of Intestinal Microecology during Mesenchymal Stem Cell-Based Therapy for Mouse Acute Liver Injury. <i>Stem Cells International</i> , 2019, 2019, 1-14.	1.2	24
138	Lipopolysaccharide protects against acetaminophen-induced hepatotoxicity by reducing oxidative stress via the TNF-Î±/TNFR1 pathway. <i>Biochemical and Biophysical Research Communications</i> , 2019, 513, 623-630.	1.0	6
139	Effect of the sulfation pattern of sea cucumber-derived fucoidan oligosaccharides on modulating metabolic syndromes and gut microbiota dysbiosis caused by HFD in mice. <i>Journal of Functional Foods</i> , 2019, 55, 193-210.	1.6	38
140	The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity. <i>Frontiers in Immunology</i> , 2019, 10, 82.	2.2	157
141	Mussel polysaccharide Î±-D-glucan (MP-A) protects against non-alcoholic fatty liver disease via maintaining the homeostasis of gut microbiota and regulating related gut-liver axis signaling pathways. <i>International Journal of Biological Macromolecules</i> , 2019, 130, 68-78.	3.6	40
142	A Peripheral Blood DNA Methylation Signature of Hepatic Fat Reveals a Potential Causal Pathway for Nonalcoholic Fatty Liver Disease. <i>Diabetes</i> , 2019, 68, 1073-1083.	0.3	41
143	Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters. <i>Acta Pharmaceutica Sinica B</i> , 2019, 9, 702-710.	5.7	121
144	Association between Sleep Disturbances and Liver Status in Obese Subjects with Nonalcoholic Fatty Liver Disease: A Comparison with Healthy Controls. <i>Nutrients</i> , 2019, 11, 322.	1.7	29
145	Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease. <i>BioMed Research International</i> , 2019, 2019, 1-10.	0.9	37
146	Backbone 1H, 13C, and 15N resonance assignments of BoMan26A, a Î²-mannanase of the glycoside hydrolase family 26 from the human gut bacterium <i>Bacteroides ovatus</i> . <i>Biomolecular NMR Assignments</i> , 2019, 13, 213-218.	0.4	1
147	The Impact of Past and Current Alcohol Consumption Patterns on Progression of Carotid Intima-Media Thickness Among Women and Men Living with HIV Infection. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 695-703.	1.4	1

#	ARTICLE	IF	CITATIONS
148	Role of the intestinal microbiome in liver fibrosis development and new treatment strategies. Translational Research, 2019, 209, 22-38.	2.2	51
149	Obesity and Nonalcoholic Fatty Liver Disease in Children. , 2019, , 209-222.		1
150	Nutritional and Dietary Interventions for Nonalcoholic Fatty Liver Disease. , 2019, , 357-372.		3
151	The effect of synbiotics supplement on alcohol use disorders identification test and biochemical parameters, gamma glutamyl transferase, lipopolysaccharide and immunoglobulin a levels, in high risk alcoholics. Asian Journal of Medical Sciences, 2019, 11, 1-6.	0.0	3
153	Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?. Nutrients, 2019, 11, 2837.	1.7	64
154	Advances in Gut Microbiota of Viral Hepatitis Cirrhosis. BioMed Research International, 2019, 2019, 1-9.	0.9	20
155	The Role of the Gut Microbiota in Lipid and Lipoprotein Metabolism. Journal of Clinical Medicine, 2019, 8, 2227.	1.0	82
156	The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease – a systematic review and meta-analysis. European Journal of Gastroenterology and Hepatology, 2019, 31, 703-715.	0.8	36
157	Association between Helicobacter pylori infection and nonalcoholic fatty liver. Medicine (United Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 4	0.4	28
158	Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes. , 2019, , 91-99.		0
159	Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease. Drugs, 2019, 79, 75-84.	4.9	17
160	Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases. Advanced Science, 2019, 6, 1801585.	5.6	110
161	Enhancing Clinical Efficacy through the Gut Microbiota: A New Field of Traditional Chinese Medicine. Engineering, 2019, 5, 40-49.	3.2	21
162	Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome. Obesity Reviews, 2019, 20, 599-611.	3.1	59
163	Antimicrobial proteins: intestinal guards to protect against liver disease. Journal of Gastroenterology, 2019, 54, 209-217.	2.3	33
164	Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults. Expert Opinion on Pharmacotherapy, 2019, 20, 69-82.	0.9	15
165	The Role of the Bacterial Microbiota in Alcoholic and Non-alcoholic Fatty Liver Disease. , 2019, , 89-104.		0
166	Maternal prebiotic supplementation reduces fatty liver development in offspring through altered microbial and metabolomic profiles in rats. FASEB Journal, 2019, 33, 5153-5167.	0.2	39

#	ARTICLE	IF	CITATIONS
167	Antibiotic Perturbation of Gut Microbiota Dysregulates Osteoimmune Cross Talk in Postpubertal Skeletal Development. <i>American Journal of Pathology</i> , 2019, 189, 370-390.	1.9	39
168	A Review of Non-Alcoholic Fatty Liver Disease in HIV-Infected Patients: The Next Big Thing?. <i>Infectious Diseases and Therapy</i> , 2019, 8, 33-50.	1.8	50
169	Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH. <i>Transplantation</i> , 2019, 103, e1-e13.	0.5	266
170	Potential mechanisms linking gut microbiota and portal hypertension. <i>Liver International</i> , 2019, 39, 598-609.	1.9	34
171	Effects of the 1975 Japanese diet on the gut microbiota in younger adults. <i>Journal of Nutritional Biochemistry</i> , 2019, 64, 121-127.	1.9	27
172	Adipose may actively delay progression of NAFLD by releasing tumor-suppressing, anti-fibrotic miR-122 into circulation. <i>Obesity Reviews</i> , 2019, 20, 108-118.	3.1	35
173	Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD. <i>Critical Reviews in Food Science and Nutrition</i> , 2019, 59, 2494-2505.	5.4	47
174	Dietary Ginkgo biloba leaf extracts supplementation improved immunity and intestinal morphology, antioxidant ability and tight junction proteins mRNA expression of hybrid groupers (<i>Epinephelus</i>) Tj ETQq1 1 0.784314 rgBT /Overlock 1 98. 611-618.	1.6	23
175	Alterations of endogenous sphingolipid metabolism in cardiometabolic diseases: Towards novel therapeutic approaches. <i>Biochimie</i> , 2020, 169, 133-143.	1.3	18
176	WZ66, a novel acetyl-CoA carboxylase inhibitor, alleviates nonalcoholic steatohepatitis (NASH) in mice. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 336-347.	2.8	17
177	Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. <i>Endocrine Reviews</i> , 2020, 41, 66-117.	8.9	134
178	Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 40-52.	8.2	203
179	Role of gut microbiota in liver disease. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G84-G98.	1.6	78
180	Changes of gut microbiota during silybin-mediated treatment of high-fat diet-induced non-alcoholic fatty liver disease in mice. <i>Hepatology Research</i> , 2020, 50, 5-14.	1.8	39
181	Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 125-133.	1.9	40
182	The gut-liver-kidney axis: Novel regulator of fatty liver associated chronic kidney disease. <i>Pharmacological Research</i> , 2020, 152, 104617.	3.1	50
183	Amelioration of non-alcoholic steatohepatitis by Qushi Huayu decoction is associated with inhibition of the intestinal mitogen-activated protein kinase pathway. <i>Phytomedicine</i> , 2020, 66, 153135.	2.3	29
184	Ablation of Hmgb1 in Intestinal Epithelial Cells Causes Intestinal Lipid Accumulation and Reduces NASH in Mice. <i>Hepatology Communications</i> , 2020, 4, 92-108.	2.0	13

#	ARTICLE	IF	CITATIONS
185	Herbal drug discovery for the treatment of nonalcoholic fatty liver disease. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 3-18.	5.7	121
186	Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. <i>Journal of Gastroenterology</i> , 2020, 55, 142-158.	2.3	105
187	Coordinated changes of gut microbiome and lipidome differentiates nonalcoholic steatohepatitis (NASH) from isolated steatosis. <i>Liver International</i> , 2020, 40, 622-637.	1.9	32
188	<i>Lactobacillus plantarum</i> LP104 ameliorates hyperlipidemia induced by AMPK pathways in C57BL/6N mice fed high-fat diet. <i>Journal of Functional Foods</i> , 2020, 64, 103665.	1.6	36
189	The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. <i>Hepatology International</i> , 2020, 14, 889-919.	1.9	422
190	Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease. <i>Cells</i> , 2020, 9, 1638.	1.8	76
191	Transcriptional Regulation in Non-Alcoholic Fatty Liver Disease. <i>Metabolites</i> , 2020, 10, 283.	1.3	23
192	Can You Trust Your Gut? Implicating a Disrupted Intestinal Microbiome in the Progression of NAFLD/NASH. <i>Frontiers in Endocrinology</i> , 2020, 11, 592157.	1.5	28
193	Naringin Attenuates High Fat Diet Induced Non-alcoholic Fatty Liver Disease and Gut Bacterial Dysbiosis in Mice. <i>Frontiers in Microbiology</i> , 2020, 11, 585066.	1.5	100
194	Microbiota Transplant in the Treatment of Obesity and Diabetes: Current and Future Perspectives. <i>Frontiers in Microbiology</i> , 2020, 11, 590370.	1.5	40
195	Amelioration of non-alcoholic fatty liver disease by sodium butyrate is linked to the modulation of intestinal tight junctions in db/db mice. <i>Food and Function</i> , 2020, 11, 10675-10689.	2.1	33
196	Organismal Fructose Metabolism in Health and Non-Alcoholic Fatty Liver Disease. <i>Biology</i> , 2020, 9, 405.	1.3	11
197	Constant Light Exposure Alters Gut Microbiota and Promotes the Progression of Steatohepatitis in High Fat Diet Rats. <i>Frontiers in Microbiology</i> , 2020, 11, 1975.	1.5	30
198	Advances in the Involvement of Gut Microbiota in Pathophysiology of NAFLD. <i>Frontiers in Medicine</i> , 2020, 7, 361.	1.2	47
199	Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5214.	1.8	134
200	Bacteriocin PJ4 from probiotic <i>Lactobacillus</i> reduced adipokine and inflammasome in high fat diet induced obesity. <i>3 Biotech</i> , 2020, 10, 355.	1.1	17
201	Microbiome and Metabolome Analyses Reveal the Disruption of Lipid Metabolism in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2020, 11, 1703.	2.2	56
202	Consumption of Wild Rice (<i>Zizania latifolia</i>) Prevents Metabolic Associated Fatty Liver Disease through the Modulation of the Gut Microbiota in Mice Model. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5375.	1.8	8

#	ARTICLE	IF	CITATIONS
203	The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease. <i>Molecular Nutrition and Food Research</i> , 2020, 64, e2000375.	1.5	37
204	Ethyl Acetate Fraction of <i>Amomum xanthioides</i> Ameliorates Nonalcoholic Fatty Liver Disease in a High-Fat Diet Mouse Model. <i>Nutrients</i> , 2020, 12, 2433.	1.7	9
205	NLR and Intestinal Dysbiosis-Associated Inflammatory Illness: Drivers or Dampers?. <i>Frontiers in Immunology</i> , 2020, 11, 1810.	2.2	33
206	Human gut microbiota/microbiome in health and diseases: a review. <i>Antonie Van Leeuwenhoek</i> , 2020, 113, 2019-2040.	0.7	473
207	<p>Gut Dysbiosis and Increased Intestinal Permeability Drive microRNAs, NLRP-3 Inflammasome and Liver Fibrosis in a Nutritional Model of Non-Alcoholic Steatohepatitis in Adult Male Sprague Dawley Rats<p>. <i>Clinical and Experimental Gastroenterology</i> , 2020, Volume 13, 351-368.	1.0	28
208	Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. <i>Journal of Clinical Medicine</i> , 2020, 9, 2648.	1.0	93
209	Administration of small-molecule guanabenz acetate attenuates fatty liver and hyperglycemia associated with obesity. <i>Scientific Reports</i> , 2020, 10, 13671.	1.6	17
210	Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5820.	1.8	38
211	Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease. <i>Cell and Bioscience</i> , 2020, 10, 140.	2.1	26
212	An Update on the Efficacy and Functionality of Probiotics for the Treatment of Non-Alcoholic Fatty Liver Disease. <i>Engineering</i> , 2021, 7, 679-686.	3.2	17
213	Liver disease in obesity and underweight: the two sides of the coin. A narrative review. <i>Eating and Weight Disorders</i> , 2021, 26, 2097-2107.	1.2	24
214	<i>Bifidobacterium animalis</i> ssp. <i>Lactis</i> 420 Mitigates Autoimmune Hepatitis Through Regulating Intestinal Barrier and Liver Immune Cells. <i>Frontiers in Immunology</i> , 2020, 11, 569104.	2.2	36
215	An Update on the Role of the Microbiome in Non-alcoholic Fatty Liver Disease Pathogenesis, Diagnosis, and Treatment. <i>Current Treatment Options in Gastroenterology</i> , 2020, 18, 270-280.	0.3	8
216	Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice. <i>Scientific Reports</i> , 2020, 10, 7440.	1.6	8
217	Bisphenol A exposure induces gut microbiota dysbiosis and consequent activation of gut-liver axis leading to hepatic steatosis in CD-1 mice. <i>Environmental Pollution</i> , 2020, 265, 114880.	3.7	71
218	<i>Lactobacillus plantarum</i> FRT10 alleviated high-fat diet-induced obesity in mice through regulating the PPARI± signal pathway and gut microbiota. <i>Applied Microbiology and Biotechnology</i> , 2020, 104, 5959-5972.	1.7	40
219	Poor Adherence to Mediterranean Diet and Serum Lipopolysaccharide Are Associated with Oxidative Stress in Patients with Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2020, 12, 1732.	1.7	33
220	Pathobiological and molecular connections involved in the high fructose and high fat diet induced diabetes associated nonalcoholic fatty liver disease. <i>Inflammation Research</i> , 2020, 69, 851-867.	1.6	7

#	ARTICLE	IF	CITATIONS
221	<i>Bifidobacterium adolescentis</i> and <i>Lactobacillus rhamnosus</i> alleviate non-alcoholic fatty liver disease induced by a high-fat, high-cholesterol diet through modulation of different gut microbiota-dependent pathways. <i>Food and Function</i> , 2020, 11, 6115-6127.	2.1	47
222	A systematic review and meta-analysis of probiotic consumption and metabolic status of athletes. <i>International Journal of Food Properties</i> , 2020, 23, 941-954.	1.3	3
223	Bacterial antigen translocation and age as BMI-independent contributing factors on systemic inflammation in NAFLD patients. <i>Liver International</i> , 2020, 40, 2182-2193.	1.9	14
224	Is bariatric surgery resolving NAFLD via microbiota-mediated bile acid ratio reversal? A comprehensive review. <i>Surgery for Obesity and Related Diseases</i> , 2020, 16, 1361-1369.	1.0	19
225	NOD2 in hepatocytes engages a liver-gut axis to protect against steatosis, fibrosis, and gut dysbiosis during fatty liver disease in mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2020, 319, E305-E314.	1.8	25
226	Liver fibrogenesis: an update on established and emerging basic concepts. <i>Archives of Biochemistry and Biophysics</i> , 2020, 689, 108445.	1.4	15
227	Western diet induces severe nonalcoholic steatohepatitis, ductular reaction, and hepatic fibrosis in liver CGI-58 knockout mice. <i>Scientific Reports</i> , 2020, 10, 4701.	1.6	17
228	Liraglutide Attenuates Nonalcoholic Fatty Liver Disease by Modulating Gut Microbiota in Rats Administered a High-Fat Diet. <i>BioMed Research International</i> , 2020, 2020, 1-10.	0.9	14
229	Interactions between resveratrol and gut microbiota affect the development of hepatic steatosis: A fecal microbiota transplantation study in high-fat diet mice. <i>Journal of Functional Foods</i> , 2020, 67, 103883.	1.6	18
230	Adipokines and Endotoxemia Correlate with Hepatic Steatosis in Non-Alcoholic Fatty Liver Disease (NAFLD). <i>Nutrients</i> , 2020, 12, 699.	1.7	33
231	Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 279-297.	8.2	539
232	Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan. <i>Nutrients</i> , 2020, 12, 820.	1.7	62
233	Maternal sucralose intake alters gut microbiota of offspring and exacerbates hepatic steatosis in adulthood. <i>Gut Microbes</i> , 2020, 11, 1043-1063.	4.3	43
234	Current and Future Treatments in the Fight against Non-Alcoholic Fatty Liver Disease. <i>Cancers</i> , 2020, 12, 1714.	1.7	28
235	The intestinal microbiota and hepatocellular carcinoma. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 223-226.	0.3	4
236	Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2020, 158, 1913-1928.	0.6	346
237	Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?. <i>Gastroenterology</i> , 2020, 158, 1881-1898.	0.6	123
238	Gut Microbial Dysbiosis Is Associated With Profibrotic Factors in Liver Fibrosis Mice. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 18.	1.8	13

#	ARTICLE	IF	CITATIONS
239	Bile acid sequestration reverses liver injury and prevents progression of nonalcoholic steatohepatitis in Western dietâ€fed mice. <i>Journal of Biological Chemistry</i> , 2020, 295, 4733-4747.	1.6	37
240	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1999-2014.e1.	0.6	1,840
241	Circadian Rhythms in the Pathogenesis and Treatment of Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1948-1966.e1.	0.6	84
242	Insoluble dietary fibre intake is associated with lower prevalence of newly-diagnosed non-alcoholic fatty liver disease in Chinese men: a large population-based cross-sectional study. <i>Nutrition and Metabolism</i> , 2020, 17, 4.	1.3	28
243	The Effects of Gelatinized Wheat Starch and High Salt Diet on Gut Microbiota and Metabolic Disorder. <i>Nutrients</i> , 2020, 12, 301.	1.7	26
245	Structural modulation of gut microbiota during alleviation of non-alcoholic fatty liver disease with <i>Gynostemma pentaphyllum</i> in rats. <i>BMC Complementary Medicine and Therapies</i> , 2020, 20, 34.	1.2	19
246	Selenium-enriched <i>Bifidobacterium longum</i> protected alcohol and high fat diet induced hepatic injury in mice. <i>Chinese Journal of Natural Medicines</i> , 2020, 18, 169-177.	0.7	16
247	Phenotyping nonâ€alcoholic fatty liver disease by the gut microbiota: Ready for prime time?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1969-1977.	1.4	27
248	<i>Lactobacillus plantarum</i> NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation. <i>Applied Microbiology and Biotechnology</i> , 2020, 104, 5273-5282.	1.7	75
249	Effects of synbiotic consumption on lipid profile: a systematic review and meta-analysis of randomized controlled clinical trials. <i>European Journal of Nutrition</i> , 2020, 59, 2857-2874.	1.8	21
250	Gut microbiota regulate cognitive deficits and amyloid deposition in a model of Alzheimerâ€™s disease. <i>Journal of Neurochemistry</i> , 2020, 155, 448-461.	2.1	49
251	Role of Gut Microbiota in Neuroendocrine Regulation of Carbohydrate and Lipid Metabolism via the Microbiota-Gut-Brain-Liver Axis. <i>Microorganisms</i> , 2020, 8, 527.	1.6	101
252	Dysbiosis of Gut Microbiota and Shortâ€Chain Fatty Acids in Acute Ischemic Stroke and the Subsequent Risk for Poor Functional Outcomes. <i>Journal of Parenteral and Enteral Nutrition</i> , 2021, 45, 518-529.	1.3	111
253	P7C3â€A20 alleviates fatty liver by shaping gut microbiota and inducing FGF21/FGF1, via the AMPâ€activated protein kinase/CREB regulated transcription coactivator 2 pathway. <i>British Journal of Pharmacology</i> , 2021, 178, 2111-2130.	2.7	27
254	The gut mycobiome: a novel player in chronic liver diseases. <i>Journal of Gastroenterology</i> , 2021, 56, 1-11.	2.3	22
255	A rational review on the effects of sweeteners and sweetness enhancers on appetite, food reward and metabolic/adiposity outcomes in adults. <i>Food and Function</i> , 2021, 12, 442-465.	2.1	21
256	Site-specific risk of colorectal neoplasms in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0245921.	1.1	11
257	Research Progress of Intestinal Flora and Health. <i>Advances in Clinical Medicine</i> , 2021, 11, 2221-2227.	0.0	2

#	ARTICLE	IF	CITATIONS
258	Gastrointestinal Dysfunction and HIV Comorbidities. <i>Current HIV/AIDS Reports</i> , 2021, 18, 57-62.	1.1	17
259	A high-fat diet and high-fat and high-cholesterol diet may affect glucose and lipid metabolism differentially through gut microbiota in mice. <i>Experimental Animals</i> , 2021, 70, 73-83.	0.7	35
260	Gut Microbiota Dysbiosis in Non-alcoholic Fatty Liver Disease. , 2021, , 475-475.		0
261	NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. <i>Journal of Clinical Medicine</i> , 2021, 10, 467.	1.0	31
262	Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates. <i>International Journal of Biological Sciences</i> , 2021, 17, 818-833.	2.6	51
263	The Comparison and Contrast on NAFLD between the East and the West: Metabolic Mechanism, Dietary Habits, and Policies. <i>E3S Web of Conferences</i> , 2021, 308, 02021.	0.2	0
264	The Role of Omic Technologies in the Study of the Human Gut Microbiome. , 2021, , 469-481.		0
265	Emerging prevalence of fatty liver disease in HIV. <i>Future Virology</i> , 2021, 16, 59-73.	0.9	1
266	Valã€Valã€Tyrã€Pro protects against nonã€alcoholic steatohepatitis in mice by modulating the gut microbiota and gutã€liver axis activation. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 1439-1455.	1.6	11
267	The Impact of Artificial Sweeteners on Body Weight Control and Glucose Homeostasis. <i>Frontiers in Nutrition</i> , 2020, 7, 598340.	1.6	62
268	Gut Microbiome and Liver Cancer. <i>Physiology in Health and Disease</i> , 2021, , 199-255.	0.2	0
269	Current treatment paradigms and emerging therapies for NAFLD/NASH. <i>Frontiers in Bioscience - Landmark</i> , 2021, 26, 206-237.	3.0	140
270	THE ROLE OF ZONULIN IN THE DEVELOPMENT OF LIVER FIBROSIS IN OBESE ADOLESCENTS. <i>Wiadomoã€ci Lekarskie</i> , 2021, 74, 77-82.	0.1	2
271	Extracellular Vesicles as Inflammatory Drivers in NAFLD. <i>Frontiers in Immunology</i> , 2020, 11, 627424.	2.2	38
272	EVALUATION OF MICROBIOCENOSIS OF LARGE INTESTINE AND INTESTINAL PERMEABILITY IN OBESE ADOLESCENTS. <i>International Medical Journal</i> , 2021, , 23-26.	0.1	0
273	Exploratory Investigation of Intestinal Structure and Function after Stroke in Mice. <i>Mediators of Inflammation</i> , 2021, 2021, 1-12.	1.4	16
274	Pathophysiological Roles of Mucosal-Associated Invariant T Cells in the Context of Gut Microbiota-Liver Axis. <i>Microorganisms</i> , 2021, 9, 296.	1.6	11
275	Fibrotic Strictures in Crohnã€™s Disease: Mechanisms and Predictive Factors. <i>Current Drug Targets</i> , 2021, 22, 241-251.	1.0	6

#	ARTICLE	IF	CITATIONS
276	Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis. <i>Biomedicines</i> , 2021, 9, 145.	1.4	20
277	Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review. <i>Antioxidants</i> , 2021, 10, 270.	2.2	104
278	Gut Microbiota Modulation by Polyphenols from <i>Aronia melanocarpa</i> of LPS-Induced Liver Diseases in Rats. <i>Journal of Agricultural and Food Chemistry</i> , 2021, 69, 3312-3325.	2.4	24
279	G protein-coupled receptors: Key molecules in metabolic associated fatty liver disease development. <i>Nutrition Research</i> , 2021, 87, 70-79.	1.3	6
280	The Role of Diagnostic Biomarkers, Omics Strategies, and Single-Cell Sequencing for Nonalcoholic Fatty Liver Disease in Severely Obese Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 930.	1.0	6
281	Epidemiology of Pediatric Nonalcoholic Fatty Liver Disease. <i>Clinical Liver Disease</i> , 2021, 17, 196-199.	1.0	38
282	Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease. <i>Nutrients</i> , 2021, 13, 1013.	1.7	18
283	Jian-Gan-Xiao-Zhi Decoction Alleviates Inflammatory Response in Nonalcoholic Fatty Liver Disease Model Rats through Modulating Gut Microbiota. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-13.	0.5	6
284	Impacts of Maternal Diet and Alcohol Consumption during Pregnancy on Maternal and Infant Gut Microbiota. <i>Biomolecules</i> , 2021, 11, 369.	1.8	15
285	Probiotic Gastrointestinal Transit and Colonization After Oral Administration: A Long Journey. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 609722.	1.8	134
286	Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease. <i>Pharmacological Research</i> , 2021, 166, 105517.	3.1	16
287	Connecting the dots: Targeting the microbiome in drug toxicity. <i>Medicinal Research Reviews</i> , 2022, 42, 83-111.	5.0	8
288	Non-Alcoholic Fatty Liver Disease in Obese Youth With Insulin Resistance and Type 2 Diabetes. <i>Frontiers in Endocrinology</i> , 2021, 12, 639548.	1.5	35
289	The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Frontiers in Immunology</i> , 2021, 12, 660179.	2.2	56
290	The Role of Gut Microbiota in Duodenal-jejunal Bypass Surgery-Induced Improvement of Hepatic Steatosis in HFD-Fed Rats. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 640448.	1.8	3
291	Dietary anthocyanins as potential natural modulators for the prevention and treatment of non-alcoholic fatty liver disease: A comprehensive review. <i>Food Research International</i> , 2021, 142, 110180.	2.9	36
292	Nonalcoholic Fatty Liver Disease: Focus on New Biomarkers and Lifestyle Interventions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3899.	1.8	20
293	Resveratrol enhances trans-intestinal cholesterol excretion through selective activation of intestinal liver X receptor alpha. <i>Biochemical Pharmacology</i> , 2021, 186, 114481.	2.0	9

#	ARTICLE	IF	CITATIONS
294	The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights. <i>Nutrients</i> , 2021, 13, 1314.	1.7	34
295	Mining Gut Microbiota From Bariatric Surgery for MAFLD. <i>Frontiers in Endocrinology</i> , 2021, 12, 612946.	1.5	5
296	Role of Insulin Resistance in MAFLD. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4156.	1.8	131
297	Antibiotic Therapy and the Gut Microbiome: Investigating the Effect of Delivery Route on Gut Pathogens. <i>ACS Infectious Diseases</i> , 2021, 7, 1283-1296.	1.8	22
298	Gut fermentation syndrome: A systematic review of case reports. <i>United European Gastroenterology Journal</i> , 2021, 9, 332-342.	1.6	28
299	Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4495.	1.8	56
300	Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development. <i>Nutrients</i> , 2021, 13, 1442.	1.7	85
301	Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis. <i>Frontiers in Endocrinology</i> , 2021, 12, 665987.	1.5	17
302	Changes in digoxin pharmacokinetics associated with hepatic P-glycoprotein upregulation in rats with non-alcoholic fatty liver disease. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 1100-1108.	1.0	2
304	The gut microbiome is associated with brain structure and function in schizophrenia. <i>Scientific Reports</i> , 2021, 11, 9743.	1.6	49
305	Prolyl Endopeptidase Gene Disruption Improves Gut Dysbiosis and Non-alcoholic Fatty Liver Disease in Mice Induced by a High-Fat Diet. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 628143.	1.8	3
306	Association between non-alcoholic fatty liver disease and the risk of biliary tract cancers: A South Korean nationwide cohort study. <i>European Journal of Cancer</i> , 2021, 150, 73-82.	1.3	15
307	Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6485.	1.8	40
308	The Role of Microbiota in Primary Sclerosing Cholangitis and Related Biliary Malignancies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6975.	1.8	22
309	Jiangzhi Ligan Decoction Inhibits GSDMD-Mediated Canonical/Noncanonical Pyroptosis Pathways and Alleviates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease. <i>Disease Markers</i> , 2021, 2021, 1-11.	0.6	6
310	Metabolomic signatures for liver tissue and cecum contents in high-fat diet-induced obese mice based on UHPLC-Q-TOF/MS. <i>Nutrition and Metabolism</i> , 2021, 18, 69.	1.3	24
311	Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism. <i>Journal of Advanced Research</i> , 2021, 34, 109-122.	4.4	51
312	Intestinal Dysbiosis and Non-Alcoholic Fatty Liver Disease. <i>Biochemistry</i> , 0, , .	0.8	4

#	ARTICLE	IF	CITATIONS
313	The Therapeutic Effects and Mechanisms of Quercetin on Metabolic Diseases: Pharmacological Data and Clinical Evidence. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-16.	1.9	64
314	Research progress on intervention effect and mechanism of protocatechuic acid on nonalcoholic fatty liver disease. <i>Critical Reviews in Food Science and Nutrition</i> , 2022, 62, 9053-9075.	5.4	14
315	Gut Microbiota as an Emerging Therapeutic Avenue for the Treatment of Nonalcoholic Fatty Liver Disease. <i>Current Pharmaceutical Design</i> , 2021, 27, 4677-4685.	0.9	7
316	Endocrine disruption in Crohn's disease: Bisphenol A enhances systemic inflammatory response in patients with gut barrier translocation of dysbiotic microbiota products. <i>FASEB Journal</i> , 2021, 35, e21697.	0.2	17
317	Unhealthy Lifestyle and Gut Dysbiosis: A Better Understanding of the Effects of Poor Diet and Nicotine on the Intestinal Microbiome. <i>Frontiers in Endocrinology</i> , 2021, 12, 667066.	1.5	82
318	The pathogenic oral-gut-liver axis: new understandings and clinical implications. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 727-736.	1.3	18
319	Dysregulation of autophagy acts as a pathogenic mechanism of non-alcoholic fatty liver disease (NAFLD) induced by common environmental pollutants. <i>Ecotoxicology and Environmental Safety</i> , 2021, 217, 112256.	2.9	15
320	Herbal therapy for ameliorating nonalcoholic fatty liver disease via rebuilding the intestinal microecology. <i>Chinese Medicine</i> , 2021, 16, 62.	1.6	8
321	The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8161.	1.8	29
322	Beneficial Effects of Organosulfur Compounds from <i>Allium cepa</i> on Gut Health: A Systematic Review. <i>Foods</i> , 2021, 10, 1680.	1.9	28
323	Bariatric Surgery and Liver Disease: General Considerations and Role of the Gut-Liver Axis. <i>Nutrients</i> , 2021, 13, 2649.	1.7	24
324	Oleanolic Acid Targets the Gut-Liver Axis to Alleviate Metabolic Disorders and Hepatic Steatosis. <i>Journal of Agricultural and Food Chemistry</i> , 2021, 69, 7884-7897.	2.4	63
325	Vitamin D ameliorates high-fat-diet-induced hepatic injury via inhibiting pyroptosis and alters gut microbiota in rats. <i>Archives of Biochemistry and Biophysics</i> , 2021, 705, 108894.	1.4	30
326	Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD. <i>Inflammation Research</i> , 2021, 70, 765-776.	1.6	8
327	Molecular and Pathophysiological Links between Metabolic Disorders and Inflammatory Bowel Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9139.	1.8	18
328	Probiotics Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats via Gut Microbiota/FXR/FGF15 Signaling Pathway. <i>Journal of Immunology Research</i> , 2021, 2021, 1-10.	0.9	24
329	The promise of the gut microbiome as part of individualized treatment strategies. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 7-25.	8.2	60
330	Altered Fecal Microbiotas and Organic Acid Concentrations Indicate Possible Gut Dysbiosis in University Rugby Players: An Observational Study. <i>Microorganisms</i> , 2021, 9, 1687.	1.6	5

#	ARTICLE	IF	CITATIONS
331	Associations of acrylamide with non-alcoholic fatty liver disease in American adults: a nationwide cross-sectional study. <i>Environmental Health</i> , 2021, 20, 98.	1.7	9
332	Probiotic-prebiotic-synbiotic modulation of (YAP1, LATS1 and NF2 mRNAs/miR-1205/lncRNA SRD5A3-AS1) panel in NASH animal model. <i>Biomedicine and Pharmacotherapy</i> , 2021, 140, 111781.	2.5	11
333	Metabolomic Predictors of Non-alcoholic Steatohepatitis and Advanced Fibrosis in Children. <i>Frontiers in Microbiology</i> , 2021, 12, 713234.	1.5	14
334	The effects of Ramadan intermittent fasting on liver function in healthy adults: A systematic review, meta-analysis, and meta-regression. <i>Diabetes Research and Clinical Practice</i> , 2021, 178, 108951.	1.1	31
335	Myricetin supplementation decreases hepatic lipid synthesis and inflammation by modulating gut microbiota. <i>Cell Reports</i> , 2021, 36, 109641.	2.9	55
336	Hepatic microbiome in healthy lean and obese humans. <i>JHEP Reports</i> , 2021, 3, 100299.	2.6	15
337	Non-alcoholic fatty liver disease: Update on treatment options and translational implications of sleep disruption. <i>Annals of Clinical Gastroenterology and Hepatology</i> , 2021, 5, 032-038.	0.1	1
338	Inflammatory and fibrotic mechanisms in NAFLD—Implications for new treatment strategies. <i>Journal of Internal Medicine</i> , 2022, 291, 11-31.	2.7	45
339	Arsenic exposure induces intestinal barrier damage and consequent activation of gut-liver axis leading to inflammation and pyroptosis of liver in ducks. <i>Science of the Total Environment</i> , 2021, 788, 147780.	3.9	70
340	Leaky Gut and Gut-Liver Axis in Liver Cirrhosis: Clinical Studies Update. <i>Gut and Liver</i> , 2021, 15, 666-676.	1.4	54
341	Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 742382.	1.1	22
342	An investigation of cross-sectional associations of a priori—selected dietary components with circulating bile acids. <i>American Journal of Clinical Nutrition</i> , 2021, 114, 1802-1813.	2.2	11
343	Regulatory effects of Lactobacillus fermented black barley on intestinal microbiota of NAFLD rats. <i>Food Research International</i> , 2021, 147, 110467.	2.9	16
344	Targeting Gut—Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension. <i>Livers</i> , 2021, 1, 147-179.	0.8	3
345	Regulatory mechanisms of energy metabolism and inflammation in oleic acid—treated HepG2 cells from <i>Lactobacillus acidophilus</i> NX2—extract. <i>Journal of Food Biochemistry</i> , 2021, 45, e13925.	1.2	5
346	Changing clinical management of NAFLD in Asia. <i>Liver International</i> , 2022, 42, 1955-1968.	1.9	18
347	Hepatic protective effects of Shenling Baizhu powder, a herbal compound, against inflammatory damage via TLR4/NLRP3 signalling pathway in rats with nonalcoholic fatty liver disease. <i>Journal of Integrative Medicine</i> , 2021, 19, 428-438.	1.4	16
348	Phillygenin Attenuates Carbon Tetrachloride-Induced Liver Fibrosis via Modulating Inflammation and Gut Microbiota. <i>Frontiers in Pharmacology</i> , 2021, 12, 756924.	1.6	17

#	ARTICLE	IF	CITATIONS
349	Guanine Nucleotideâ€Binding Protein G(i) Subunit Alpha 2 Exacerbates NASH Progression by Regulating Peroxiredoxin 1â€Related Inflammation and Lipophagy. <i>Hepatology</i> , 2021, 74, 3110-3126.	3.6	9
350	Traditional Chinese Medicine Ganshuang Granules Attenuate CCl ₄ -Induced Hepatic Fibrosis by Modulating Gut Microbiota. <i>Chemistry and Biodiversity</i> , 2021, 18, e2100520.	1.0	8
351	Dietary broccoli improves markers associated with glucose and lipid metabolism through modulation of gut microbiota in mice. <i>Nutrition</i> , 2021, 90, 111240.	1.1	11
352	Lactic acid bacteria alleviate liver damage caused by perfluorooctanoic acid exposure via antioxidant capacity, biosorption capacity and gut microbiota regulation. <i>Ecotoxicology and Environmental Safety</i> , 2021, 222, 112515.	2.9	18
353	A botanical dietary supplement from white peony and licorice attenuates nonalcoholic fatty liver disease by modulating gut microbiota and reducing inflammation. <i>Phytomedicine</i> , 2021, 91, 153693.	2.3	16
354	Mechanisms of traditional Chinese medicine in modulating gut microbiota metabolites-mediated lipid metabolism. <i>Journal of Ethnopharmacology</i> , 2021, 278, 114207.	2.0	25
355	Luteolin alleviates non-alcoholic fatty liver disease in rats via restoration of intestinal mucosal barrier damage and microbiota imbalance involving in gut-liver axis. <i>Archives of Biochemistry and Biophysics</i> , 2021, 711, 109019.	1.4	47
356	Kaempferol prevents the progression from simple steatosis to non-alcoholic steatohepatitis by inhibiting the NF-ÎB pathway in oleic acid-induced HepG2 cells and high-fat diet-induced rats. <i>Journal of Functional Foods</i> , 2021, 85, 104655.	1.6	19
357	Commentary on â€Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trialâ€. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 699-701.	0.7	0
358	Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases. <i>World Journal of Gastroenterology</i> , 2021, 27, 6161-6179.	1.4	12
359	Pharmacokinetic herb-disease-drug interactions: Effect of ginkgo biloba extract on the pharmacokinetics of pitavastatin, a substrate of Oatp1b2, in rats with non-alcoholic fatty liver disease. <i>Journal of Ethnopharmacology</i> , 2021, 280, 114469.	2.0	15
360	Fecal Fungi Dysbiosis in Nonalcoholic Fatty Liver Disease. <i>Obesity</i> , 2021, 29, 350-358.	1.5	13
361	Influence of a Biotechnologically Produced Oyster Mushroom (<i>Pleurotus sajor-caju</i>) on the Gut Microbiota and Microbial Metabolites in Obese Zucker Rats. <i>Journal of Agricultural and Food Chemistry</i> , 2021, 69, 1524-1535.	2.4	11
362	The Therapeutic Efficacy of Curcumin vs. Metformin in Modulating the Gut Microbiota in NAFLD Rats: A Comparative Study. <i>Frontiers in Microbiology</i> , 2020, 11, 555293.	1.5	27
363	The pathophysiology of gutâ€liver connection. , 2021, , 97-122.		0
364	Summary and perspective for future research on the contribution of microbiota in visceral and neurological disorders. , 2021, , 345-356.		0
365	Using AUDIT Scores to Identify Synbiotic Supplement Effect in High-Risk Alcoholics. <i>Lecture Notes in Electrical Engineering</i> , 2021, , 143-152.	0.3	0
366	Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis. <i>Metabolomics</i> , 2021, 17, 12.	1.4	37

#	ARTICLE	IF	CITATIONS
367	Fetal Alcohol Spectrum Disorder: Embryogenesis Under Reduced Retinoic Acid Signaling Conditions. <i>Sub-Cellular Biochemistry</i> , 2020, 95, 197-225.	1.0	13
368	Pathophysiological mechanisms underlying MAFLD. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 1875-1887.	1.8	75
369	ACE2: from protection of liver disease to propagation of COVID-19. <i>Clinical Science</i> , 2020, 134, 3137-3158.	1.8	35
371	Diospyros kaki and Citrus unshiu Mixture Improves Disorders of Lipid Metabolism in Nonalcoholic Fatty Liver Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2020, 2020, 1-12.	0.8	13
372	Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases. <i>World Journal of Clinical Cases</i> , 2020, 8, 1361-1384.	0.3	69
373	Skeletal Muscle Dysfunction in the Development and Progression of Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 1-10.	0.7	31
374	MANAGEMENT OF ENDOCRINE DISEASE: Non-alcoholic fatty liver disease: a multidisciplinary approach towards a cardiometabolic liver disease. <i>European Journal of Endocrinology</i> , 2020, 183, R57-R73.	1.9	24
375	The additive effects of the TM6SF2 E167K and PNPLA3 I148M polymorphisms on lipid metabolism. <i>Oncotarget</i> , 2017, 8, 74209-74216.	0.8	15
376	Molecular links between non-alcoholic fatty liver disease and hepatocellular carcinoma. <i>Hepatoma Research</i> , 2019, 2019, 42.	0.6	31
377	Does Gut-Microbiome Interaction Protect against Obesity and Obesity-Associated Metabolic Disorders?. <i>Microorganisms</i> , 2021, 9, 18.	1.6	15
378	Aging, Gut Microbiota and Metabolic Diseases: Management through Physical Exercise and Nutritional Interventions. <i>Nutrients</i> , 2021, 13, 16.	1.7	24
379	Nonalcoholic fatty liver disease and portal hypertension. <i>Exploration of Medicine</i> , 2020, 1, 149-169.	1.5	25
380	Trimethylamine N-oxide attenuates high-fat high-cholesterol diet-induced steatohepatitis by reducing hepatic cholesterol overload in rats. <i>World Journal of Gastroenterology</i> , 2019, 25, 2450-2462.	1.4	51
381	Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation. <i>World Journal of Gastroenterology</i> , 2019, 25, 4814-4834.	1.4	101
382	Intestinal permeability after Mediterranean diet and low-fat diet in non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2019, 25, 509-520.	1.4	50
383	New strain of <i>Pediococcus pentosaceus</i> alleviates ethanol-induced liver injury by modulating the gut microbiota and short-chain fatty acid metabolism. <i>World Journal of Gastroenterology</i> , 2020, 26, 6224-6240.	1.4	38
384	Metabolomic Biomarkers in the Diagnosis of Non-Alcoholic Fatty Liver Disease. <i>Hepatitis Monthly</i> , 2019, 19, .	0.1	21
385	Alteration of the gut microbiota associated with childhood obesity by 16S rRNA gene sequencing. <i>PeerJ</i> , 2020, 8, e8317.	0.9	74

#	ARTICLE	IF	CITATIONS
386	Ursolic acid improves the bacterial community mapping of the intestinal tract in liver fibrosis mice. PeerJ, 2020, 8, e9050.	0.9	13
387	Gut microbiota of obese and diabetic Thai subjects and interplay with dietary habits and blood profiles. PeerJ, 2020, 8, e9622.	0.9	7
388	High alcohol-producing <i>Klebsiella pneumoniae</i> causes fatty liver disease through 2,3-butanediol fermentation pathway <i>in vivo</i> . Gut Microbes, 2021, 13, 1979883.	4.3	20
390	Gut Microbiota-Related Cellular and Molecular Mechanisms in the Progression of Nonalcoholic Fatty Liver Disease. Cells, 2021, 10, 2634.	1.8	13
391	Multidirectional facets of obesity management in the metabolic syndrome population after liver transplantation. Immunity, Inflammation and Disease, 2021, , .	1.3	4
392	Green Plant Pigment, Chlorophyllin, Ameliorates Non-alcoholic Fatty Liver Diseases (NAFLDs) Through Modulating Gut Microbiome in Mice. Frontiers in Physiology, 2021, 12, 739174.	1.3	3
393	Oral Pathobiont-Induced Changes in Gut Microbiota Aggravate the Pathology of Nonalcoholic Fatty Liver Disease in Mice. Frontiers in Immunology, 2021, 12, 766170.	2.2	32
394	<i>E. coli</i> and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants. Hepatology, 2022, 75, 266-279.	3.6	18
395	Risk factors of nonalcoholic fatty liver disease in lean body mass population: A systematic review and meta-analysis. JGH Open, 2021, 5, 1236-1249.	0.7	11
396	Tuber flours improve intestinal health and modulate gut microbiota composition. Food Chemistry: X, 2021, 12, 100145.	1.8	1
397	A pilot study of microbial signatures of liver disease in those with HIV mono-infection in Rio de Janeiro, Brazil. Aids, 2022, 36, 49-58.	1.0	6
399	Multi-Omic Predictors of Steatohepatitis and Advanced Fibrosis in Children. SSRN Electronic Journal, 0, , .	0.4	0
402	Influence of the intestinal microbiota on the formation and development of non-alcoholic fatty liver disease in children. Zdravĕ Rebenka, 2018, 13, 776-782.	0.0	0
403	Liver Cirrhosis with Steatohepatitis: Nonalcoholic Steatohepatitis and Alcoholic Steatohepatitis. , 2019, , 1-21.		0
404	Changes of intestinal short chain fatty acids in patients with hepatitis-B-related acute-on-chronic liver failure. World Chinese Journal of Digestology, 2019, 27, 408-414.	0.0	0
405	Changes of intestinal short chain fatty acids in patients with hepatitis-B-related acute-on-chronic liver failure. World Chinese Journal of Digestology, 2019, 27, 409-415.	0.0	0
407	The phenomenon of intestinal permeability and its association with cardiovascular disease. Current status. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 2474.	0.4	2
408	Fat of the Gut: Epithelial Phospholipids in Inflammatory Bowel Diseases. International Journal of Molecular Sciences, 2021, 22, 11682.	1.8	26

#	ARTICLE	IF	CITATIONS
409	Dextran Sulfate Sodium Salt-Induced Colitis Aggravates Gut Microbiota Dysbiosis and Liver Injury in Mice With Non-alcoholic Steatohepatitis. <i>Frontiers in Microbiology</i> , 2021, 12, 756299.	1.5	17
410	Preventive and therapeutic role of betaine in liver disease: A review on molecular mechanisms. <i>European Journal of Pharmacology</i> , 2021, 912, 174604.	1.7	22
411	Intestinal barrier dysfunction and alcoholic liver disease. <i>World Chinese Journal of Digestology</i> , 2019, 27, 1179-1192.	0.0	1
412	Serum zinc level and dietary zinc intake status in non-alcoholic fatty liver disease: A meta-analysis and systematic review. <i>Hepatology Forum</i> , 2020, , .	0.3	2
413	State of gut microbiota and dietary preferences in obese adolescents. <i>Acta Medica Leopoliensia</i> , 2020, 26, 40-46.	0.0	0
415	Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications. <i>Saudi Journal of Gastroenterology</i> , 2021, 27, 319-330.	0.5	10
416	Gut microbiota and related metabolites in the pathogenesis of nonalcoholic steatohepatitis and its resolution after bariatric surgery. <i>Obesity Reviews</i> , 2022, 23, e13367.	3.1	7
419	Exogenous and Endogenous Serine Deficiency Exacerbates Hepatic Lipid Accumulation. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 4232704.	1.9	0
420	Exogenous and Endogenous Serine Deficiency Exacerbates Hepatic Lipid Accumulation. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-10.	1.9	7
421	Aryl Hydrocarbon Receptor (AhR) Activation by 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) Dose-Dependently Shifts the Gut Microbiome Consistent with the Progression of Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12431.	1.8	5
422	Possibilities of non-pharmacological correction of intestinal microbiota in patients with non-alcoholic fatty liver disease. <i>Modern Gastroenterology</i> , 2020, .	0.1	1
423	Development of Thyroid Hormones and Synthetic Thyromimetics in Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1102.	1.8	8
424	Plasma Alkylresorcinol Metabolite, a Biomarker for Whole-Grain Intake, Is Inversely Associated with Risk of Nonalcoholic Fatty Liver Disease in a Case-Control Study of Chinese Adults. <i>Journal of Nutrition</i> , 2022, 152, 1052-1058.	1.3	5
425	Probiotics and the gut-liver axis. , 2022, , 467-481.		0
426	Selected transgenic murine models of human autoimmune liver diseases. <i>Pharmacological Reports</i> , 2022, 74, 263-272.	1.5	2
427	<i>N</i> -Acetylcysteine alleviates high fat diet-induced hepatic steatosis and liver injury via regulating the intestinal microecology in mice. <i>Food and Function</i> , 2022, 13, 3368-3380.	2.1	16
428	A disease-promoting role of the intestinal mycobiome in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2022, 76, 765-767.	1.8	2
429	Research progress on the relationship between TM6SF2 rs58542926 polymorphism and non-alcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, , 1-11.	1.4	8

#	ARTICLE	IF	CITATIONS
430	Gut Microbiota and Short Chain Fatty Acids: Implications in Glucose Homeostasis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1105.	1.8	215
431	Deciphering the Effective Constituents and Mechanisms of <i>Portulaca oleracea</i> L. for Treating NASH via Integrating Bioinformatics Analysis and Experimental Pharmacology. <i>Frontiers in Pharmacology</i> , 2021, 12, 818227.	1.6	5
432	Chronic lead exposure induces fatty liver disease associated with the variations of gut microbiota. <i>Ecotoxicology and Environmental Safety</i> , 2022, 232, 113257.	2.9	33
433	Circadian Rhythms, the Gut Microbiome, and Metabolic Disorders. , 2022, 1, 93-105.		10
434	Multimiomics Analysis Reveals the Impact of Microbiota on Host Metabolism in Hepatic Steatosis. <i>Advanced Science</i> , 2022, 9, e2104373.	5.6	23
435	Intestinal Barrier and Permeability in Health, Obesity and NAFLD. <i>Biomedicines</i> , 2022, 10, 83.	1.4	71
436	Therapeutic Opportunities of IL-22 in Non-Alcoholic Fatty Liver Disease: From Molecular Mechanisms to Clinical Applications. <i>Biomedicines</i> , 2021, 9, 1912.	1.4	13
437	Heat-Inactivated <i>Akkermansia muciniphila</i> Improves Gut Permeability but Does Not Prevent Development of Non-Alcoholic Steatohepatitis in Diet-Induced Obese <i>Leiden</i> Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2325.	1.8	10
438	<i>Helicobacter pylori</i> infection is not an independent risk factor of non-alcoholic fatty liver disease in China. <i>BMC Gastroenterology</i> , 2022, 22, 81.	0.8	8
439	Relationship Between Hepatic Gene Expression, Intestinal Microbiota, and Inferred Functional Metagenomic Analysis in NAFLD. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00466.	1.3	8
440	The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC. <i>Biomedicines</i> , 2022, 10, 524.	1.4	42
441	The Microbiota-Gut-Brain Axis in Alzheimer's Disease: A Review of Taxonomic Alterations and Potential Avenues for Interventions. <i>Archives of Clinical Neuropsychology</i> , 2022, 37, 595-607.	0.3	22
442	Targeting Gut Microbiota With Natural Polysaccharides: Effective Interventions Against High-Fat Diet-Induced Metabolic Diseases. <i>Frontiers in Microbiology</i> , 2022, 13, 859206.	1.5	16
443	Microalgae-based oral microcarriers for gut microbiota homeostasis and intestinal protection in cancer radiotherapy. <i>Nature Communications</i> , 2022, 13, 1413.	5.8	78
444	Oral and Gut Microbial Dysbiosis and Non-alcoholic Fatty Liver Disease: The Central Role of <i>Porphyromonas gingivalis</i> . <i>Frontiers in Medicine</i> , 2022, 9, 822190.	1.2	18
446	Development, Characterization, and Investigation of In Vivo Targeted Delivery Efficacy of Luteolin-Loaded, Eudragit S100-Coated mPEG-PLGA Nanoparticles. <i>AAPS PharmSciTech</i> , 2022, 23, 100.	1.5	11
447	Retrorsine Cooperates with Gut Microbiota to Promote Hepatic Sinusoidal Obstruction Syndrome by Disrupting the Gut Barrier. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	2
448	Possible correlation between high circulatory levels of trimethylamine-N-oxide and CYP2C19 polymorphisms of hepatic flavin containing monooxygenase 3 in Kurdish Population with non-alcoholic fatty liver disease. <i>Molecular Biology Reports</i> , 2022, 49, 5927-5937.	1.0	4

#	ARTICLE	IF	CITATIONS
449	Vine Tea (<i>Ampelopsis grossedentata</i>) Extract Attenuates CCl ₄ -Induced Liver Injury by Restoring Gut Microbiota Dysbiosis in Mice. <i>Molecular Nutrition and Food Research</i> , 2022, 66, e2100892.	1.5	11
450	Effect of Jiangan-Jiangzhi Pill on Gut Microbiota and Chronic Inflammatory Response in Rats with Non-Alcoholic Fatty Liver. <i>Chemistry and Biodiversity</i> , 2022, 19, .	1.0	5
451	2,3,5,4-tetrahydroxy-stilbene-2-O-β-D-glucoside ameliorates NAFLD via attenuating hepatic steatosis through inhibiting mitochondrial dysfunction dependent on SIRT5. <i>Phytomedicine</i> , 2022, 99, 153994.	2.3	6
452	Lactobacillus plantarum MA2 Ameliorates Methionine and Choline-Deficient Diet Induced Non-Alcoholic Fatty Liver Disease in Rats by Improving the Intestinal Microecology and Mucosal Barrier. <i>Foods</i> , 2021, 10, 3126.	1.9	12
453	Correlation between Gut Microbiota, its Metabolic Products, and their Association with Liver Enzymes among Sample of Egyptian Females. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2022, 10, 1797-1804.	0.1	0
454	Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model. <i>Frontiers in Pharmacology</i> , 2021, 12, 788558.	1.6	34
455	Angiotensin Converting Enzyme ² Therapy Improves Liver Fibrosis and Glycemic Control in Diabetic Mice With Fatty Liver. <i>Hepatology Communications</i> , 2022, 6, 1056-1072.	2.0	5
456	Soluble Polysaccharide Derived from Laminaria japonica Attenuates Obesity-Related Nonalcoholic Fatty Liver Disease Associated with Gut Microbiota Regulation. <i>Marine Drugs</i> , 2021, 19, 699.	2.2	19
457	Potential Natural Compounds for the Prevention and Treatment of Nonalcoholic Fatty Liver Disease: A Review on Molecular Mechanisms. <i>Current Molecular Pharmacology</i> , 2021, 15, .	0.7	1
458	Non-Alcoholic Fatty Liver Disease (NAFLD) and Bariatric/Metabolic Surgery as Its Treatment Option: A Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 5721.	1.0	24
459	Tilapia-Head Chondroitin Sulfate Protects against Nonalcoholic Fatty Liver Disease via Modulating the Gut-Liver Axis in High-Fat-Diet-Fed C57BL/6 Mice. <i>Foods</i> , 2022, 11, 922.	1.9	4
460	Hepatoprotection of Probiotics Against Non-Alcoholic Fatty Liver Disease in vivo: A Systematic Review. <i>Frontiers in Nutrition</i> , 2022, 9, 844374.	1.6	5
461	Creutzfeldt-Jakob Disease: Alterations of Gut Microbiota. <i>Frontiers in Neurology</i> , 2022, 13, 832599.	1.1	4
462	Pterostilbene and Its Derivative 3-Hydroxypterostilbene Ameliorated Nonalcoholic Fatty Liver Disease Through Synergistic Modulation of the Gut Microbiota and SIRT1/AMPK Signaling Pathway. <i>Journal of Agricultural and Food Chemistry</i> , 2022, 70, 4966-4980.	2.4	20
494	The Kidney in Liver Disease. , 0, , 619-638.		0
495	Bile acid metabolism and liver fibrosis following treatment with bifid triple viable capsules in nonalcoholic fatty liver disease.. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 13485-13497.	0.0	0
497	A Low Glycemic Index Mediterranean Diet Combined with Aerobic Physical Activity Rearranges the Gut Microbiota Signature in NAFLD Patients. <i>Nutrients</i> , 2022, 14, 1773.	1.7	24
498	Yiqi-Bushen-Tiaozhi Recipe Attenuated High-Fat and High-Fructose Diet Induced Nonalcoholic Steatohepatitis in Mice via Gut Microbiota. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 824597.	1.8	5

#	ARTICLE	IF	CITATIONS
499	Salvia miltiorrhiza Bge. (Danshen) in the Treating Non-alcoholic Fatty Liver Disease Based on the Regulator of Metabolic Targets. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 842980.	1.1	2
500	Phospholipids in non-alcoholic fatty liver disease. <i>Meditinskiy Sovet</i> , 2022, , 92-99.	0.1	0
501	Impact of Helicobacter pylori Eradication on the Risk of Incident Nonalcoholic Fatty Liver Disease: A Cohort Study. <i>The Korean Journal of Helicobacter and Upper Gastrointestinal Research</i> , 2022, 22, 131-138.	0.1	3
502	Lactobacillus plantarum FRT4 alleviated obesity by modulating gut microbiota and liver metabolome in high-fat diet-induced obese mice. <i>Food and Nutrition Research</i> , 0, 66, .	1.2	5
503	Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5146.	1.8	22
504	Integrated analysis of multi-tissues lipidome and gut microbiome reveals microbiota-induced shifts on lipid metabolism in pigs. <i>Animal Nutrition</i> , 2022, 10, 280-293.	2.1	10
505	Peroxisome proliferator-activated receptor-alpha activation and dipeptidyl peptidase-4 inhibition target dysbiosis to treat fatty liver in obese mice. <i>World Journal of Gastroenterology</i> , 2022, 28, 1814-1829.	1.4	8
506	SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease. <i>Trends in Endocrinology and Metabolism</i> , 2022, 33, 424-442.	3.1	23
507	A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo. <i>Biomedicines</i> , 2022, 10, 1191.	1.4	2
508	Association of Metabolomic Change and Treatment Response in Patients with Non-Alcoholic Fatty Liver Disease. <i>Biomedicines</i> , 2022, 10, 1216.	1.4	4
509	Corydalis saxicola Bunting Total Alkaloids ameliorate diet-induced non-alcoholic steatohepatitis by regulating hepatic PI3K/Akt and TLR4/NF- κ B pathways in mice. <i>Biomedicine and Pharmacotherapy</i> , 2022, 151, 113132.	2.5	8
510	Antioxidant potential of <i>Pediococcus pentosaceus</i> strains from the sow milk bacterial collection in weaned piglets. <i>Microbiome</i> , 2022, 10, .	4.9	16
511	Growth, carcass parameters, biochemical and oxidative stress indices, and meat traits of duck breeds under different stocking densities. <i>Poultry Science</i> , 2022, 101, 101992.	1.5	8
512	Longitudinal 16S rRNA Sequencing Reveals Relationships among Alterations of Gut Microbiota and Nonalcoholic Fatty Liver Disease Progression in Mice. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	27
513	Caffeic acid phenethyl ester suppresses intestinal FXR signaling and ameliorates nonalcoholic fatty liver disease by inhibiting bacterial bile salt hydrolase activity. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 145-156.	2.8	12
514	Rifaximin enhances the L-carnitine-mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut-liver-muscle axis. <i>International Journal of Molecular Medicine</i> , 2022, 50, .	1.8	5
515	Increased risk of pancreatic cancer in individuals with non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2022, 12, .	1.6	8
516	Portal hypertension in nonalcoholic fatty liver disease: Challenges and perspectives. , 2022, 1, 57-65.		7

#	ARTICLE	IF	CITATIONS
517	Fufang Zhenzhu Tiaozhi Capsule Prevents Intestinal Inflammation and Barrier Disruption in Mice With Non-Alcoholic Steatohepatitis. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	4
518	Gut Microbial Profile in Asymptomatic Gallstones. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	4
519	Lactobacillus plantarum Ameliorates High-Carbohydrate Diet-Induced Hepatic Lipid Accumulation and Oxidative Stress by Upregulating Uridine Synthesis. <i>Antioxidants</i> , 2022, 11, 1238.	2.2	8
520	The Absence of STING Ameliorates Non-Alcoholic Fatty Liver Disease and Reforms Gut Bacterial Community. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
521	The Role of Gut Microbiota-Bile Acids Axis in the Progression of Non-alcoholic Fatty Liver Disease. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	6
522	The Benefit of Probiotics in Pediatric Nonalcoholic Fatty Liver Disease: A Meta-analysis of Randomized Control Trials. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2022, 75, e31-e37.	0.9	7
523	Bile acid metabolism and signaling, the microbiota, and metabolic disease. , 2022, 237, 108238.		62
524	The Role of Gut Microbiota in Some Liver Diseases: From an Immunological Perspective. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	21
525	The Gut Microbiome and Ferroptosis in MAFLD. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	5
526	Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	63
527	Microbial and Transcriptomic Profiling Reveals Diet-Related Alterations of Metabolism in Metabolic Disordered Mice. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	2
528	Polyhalogenated carbazoles induce hepatic metabolic disorders in mice via alteration in gut microbiota. <i>Journal of Environmental Sciences</i> , 2023, 127, 603-614.	3.2	7
529	The role of gut microflora dysbiosis in clinical manifestation of patients with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.. <i>International Journal of Scientific Research and Management</i> , 2022, 10, 658-667.	0.0	0
530	Metabolic and nutritional aspects of non-alcoholic fatty liver disease. , 2022, 18, 180-185.	0.0	1
531	Specific Strains of <i>Faecalibacterium prausnitzii</i> Ameliorate Nonalcoholic Fatty Liver Disease in Mice in Association with Gut Microbiota Regulation. <i>Nutrients</i> , 2022, 14, 2945.	1.7	31
532	Gut Microbiotaâ€”A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8307.	1.8	9
534	Vitamin Dâ€”VDR Novel Anti-Inflammatory Moleculesâ€”New Insights into Their Effects on Liver Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8465.	1.8	8
535	Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression. <i>Hepatology</i> , 2023, 77, 1654-1669.	3.6	19

#	ARTICLE	IF	CITATIONS
536	The Mechanisms of the Potential Probiotic <i>Lactiplantibacillus plantarum</i> against Cardiovascular Disease and the Recent Developments in its Fermented Foods. <i>Foods</i> , 2022, 11, 2549.	1.9	7
537	Combining fecal microbiome and metabolomics to reveal the disturbance of gut microbiota in liver injury and the therapeutic mechanism of shaoyao gancao decoction. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
538	Mouse model of NASH that replicates key features of the human disease and progresses to fibrosis stage 3. <i>Hepatology Communications</i> , 2022, 6, 2676-2688.	2.0	4
539	Trimethylamine-N-oxide (TMAO) mediates the crosstalk between the gut microbiota and hepatic vascular niche to alleviate liver fibrosis in nonalcoholic steatohepatitis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
540	Integrative analysis of gut microbiota and fecal metabolites in metabolic associated fatty liver disease patients. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	6
541	Duodenal CD8^+ T resident memory cell apoptosis contributes to gut barrier dysfunction and microbial translocation in early alcohol-associated liver disease in humans. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 1055-1070.	1.9	6
542	Metabolomic Characteristics of Liver and Cecum Contents in High-Fat-Diet-Induced Obese Mice Intervened with <i>Lactobacillus plantarum</i> FRT10. <i>Foods</i> , 2022, 11, 2491.	1.9	3
543	A systems biology approach to study non-alcoholic fatty liver (NAFL) in women with obesity. <i>IScience</i> , 2022, 25, 104828.	1.9	4
544	Effect of Hesperidin Supplementation on Liver Metabolomics and Gut Microbiota in a High-Fat Diet-Induced NAFLD Mice Model. <i>Journal of Agricultural and Food Chemistry</i> , 2022, 70, 11224-11235.	2.4	19
545	Research Progress of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease. <i>Advances in Clinical Medicine</i> , 2022, 12, 7249-7255.	0.0	1
546	Gut dysbiosis and metabolic diseases. <i>Progress in Molecular Biology and Translational Science</i> , 2022, , .	0.9	0
547	Phytic Acid Improves Hepatic Steatosis, Inflammation, and Oxidative Stress in High-Fat Diet (HFD)-Fed Mice by Modulating the Gut-Liver Axis. <i>Journal of Agricultural and Food Chemistry</i> , 2022, 70, 11401-11411.	2.4	12
548	Food and Gut Microbiota-Derived Metabolites in Nonalcoholic Fatty Liver Disease. <i>Foods</i> , 2022, 11, 2703.	1.9	3
549	Nonalcoholic fatty liver disease and diabetes. <i>World Journal of Diabetes</i> , 2022, 13, 668-682.	1.3	4
550	Nuciferine Protects Against High-Fat Diet-Induced Hepatic Steatosis via Modulation of Gut Microbiota and Bile Acid Metabolism in Rats. <i>Journal of Agricultural and Food Chemistry</i> , 2022, 70, 12014-12028.	2.4	27
551	Gut microbiome and microbial metabolites in NAFLD and after bariatric surgery: Correlation and causality. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	16
552	Helminth infection and helminth-derived products: A novel therapeutic option for non-alcoholic fatty liver disease. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
553	Influence of changes in the intestinal microbiome on the course and progression of metabolically associated fatty liver disease. , 0, , 38-44.		1

#	ARTICLE	IF	CITATIONS
554	Emerging trends and hotspots in the links between the gut microbiota and MAFLD from 2002 to 2021: A bibliometric analysis. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	6
555	Current Research on the Pathogenesis of NAFLD/NASH and the Gutâ€œLiver Axis: Gut Microbiota, Dysbiosis, and Leaky-Gut Syndrome. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11689.	1.8	21
556	Preventive Effects of Different Black and Dark Teas on Obesity and Non-Alcoholic Fatty Liver Disease and Modulate Gut Microbiota in High-Fat Diet Fed Mice. <i>Foods</i> , 2022, 11, 3457.	1.9	6
557	The effects of supplementation of probiotics, prebiotics, or synbiotics on patients with non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	8
558	<i>Lactobacillus sakei</i> MJM60958 as a Potential Probiotic Alleviated Non-Alcoholic Fatty Liver Disease in Mice Fed a High-Fat Diet by Modulating Lipid Metabolism, Inflammation, and Gut Microbiota. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13436.	1.8	15
559	Intestinal microbiota in the treatment of metabolically associated fatty liver disease. <i>World Journal of Clinical Cases</i> , 0, 10, 11240-11251.	0.3	2
560	The gut microbiota metabolite glycochenodeoxycholate activates TFR-ACSL4-mediated ferroptosis to promote the development of environmental toxinâ€œlinked MAFLD. <i>Free Radical Biology and Medicine</i> , 2022, 193, 213-226.	1.3	21
561	Role of <i>Akkermansia muciniphila</i> in the development of nonalcoholic fatty liver disease: current knowledge and perspectives. <i>Frontiers of Medicine</i> , 2022, 16, 667-685.	1.5	10
562	Î²-sitosterol inhibits trimethylamine production by regulating the gut microbiota and attenuates atherosclerosis in ApoEâ€œ/â€œ mice. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	6
563	Plasma Metabolomic and Lipidomic Profiling of Metabolic Dysfunction-Associated Fatty Liver Disease in Humans Using an Untargeted Multiplatform Approach. <i>Metabolites</i> , 2022, 12, 1081.	1.3	2
564	Oral Administration of Recombinant Lactoferrin-Expressing Probiotics Ameliorates Diet-Induced Lipid Accumulation and Inflammation in Non-Alcoholic Fatty Liver Disease in Mice. <i>Microorganisms</i> , 2022, 10, 2215.	1.6	5
565	Therapeutic Approach to NAFLD-NASH. , 0, , .		0
566	What do we know about nutrient-based strategies targeting molecular mechanisms associated with obesity-related fatty liver disease?. <i>Annals of Hepatology</i> , 2023, 28, 100874.	0.6	4
567	RISK FACTORS FOR HEPATOCELLULAR CARCINOMA IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE. <i>Arquivos De Gastroenterologia</i> , 0, , .	0.3	1
568	Commentary: Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: A randomized clinical trial. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	1
569	Postbiotics Prepared Using <i>Lactobacillus paracasei</i> CCFM1224 Prevent Nonalcoholic Fatty Liver Disease by Modulating the Gut Microbiota and Liver Metabolism. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13522.	1.8	15
570	Deciphering the role of gut metabolites in non-alcoholic fatty liver disease. <i>Critical Reviews in Microbiology</i> , 2023, 49, 815-833.	2.7	6
571	Multi-Omics Nutritional Approaches Targeting Metabolic-Associated Fatty Liver Disease. <i>Genes</i> , 2022, 13, 2142.	1.0	1

#	ARTICLE	IF	CITATIONS
572	Dysregulated hepatic lipid metabolism and gut microbiota associated with early-stage NAFLD in ASPP2-deficiency mice. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
573	The signatures of liver metabolomics and gut microbiota in high-fat diet fed mice supplemented with rhododendrol. <i>Food and Function</i> , 2022, 13, 13052-13063.	2.1	5
574	The Role of Senescence in NASH-Related HCC. , 2022, , 167-191.		1
575	Gut microbiome and fecal metabolic alteration in systemic lupus erythematosus patients with depression. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	3
576	Excessive consumption of the sugar rich longan fruit promoted the development of nonalcoholic fatty liver disease via mediating gut dysbiosis. <i>Food Frontiers</i> , 2023, 4, 491-510.	3.7	1
577	Circulating microbiota and metabolites: Insights into cardiovascular diseases. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, .	0.9	4
578	Molecular and cellular mechanisms underlying the hepatoprotective role of ghrelin against NAFLD progression. <i>Journal of Physiology and Biochemistry</i> , 2023, 79, 833-849.	1.3	4
579	<i>Terminalia bellirica</i> ethanol extract ameliorates nonalcoholic fatty liver disease in mice by amending the intestinal microbiota and faecal metabolites. <i>Journal of Ethnopharmacology</i> , 2023, 305, 116082.	2.0	5
580	Sea buckthorn pulp and seed oils ameliorate lipid metabolism disorders and modulate gut microbiota in C57BL/6J mice on high-fat diet. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	2
581	Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers. <i>Journal of Physiology and Biochemistry</i> , 2023, 79, 851-868.	1.3	4
582	Obeticholic acid and ferrostatin-1 differentially ameliorate non-alcoholic steatohepatitis in AMLN diet-fed ob/ob mice. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
583	Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol. <i>Nature Communications</i> , 2023, 14, .	5.8	22
584	Host Microbiomes Influence the Effects of Diet on Inflammation and Cancer. <i>Cancers</i> , 2023, 15, 521.	1.7	1
585	Changes in Lipidomics, Metabolomics, and the Gut Microbiota in CDAA-Induced NAFLD Mice after Polyene Phosphatidylcholine Treatment. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1502.	1.8	7
586	Microbiota and Liver Cancer. , 2023, , 67-90.		1
587	<i>Eucommia bark/leaf</i> extract improves HFD-induced lipid metabolism disorders via targeting gut microbiota to activate the Fiaf-LPL gut-liver axis and SCFAs-GPR43 gut-fat axis. <i>Phytomedicine</i> , 2023, 110, 154652.	2.3	7
588	Comparing Transgenic Production to Supplementation of ̳-3 PUFA Reveals Distinct But Overlapping Mechanisms Underlying Protection Against Metabolic and Hepatic Disorders. <i>Function</i> , 2023, 4, .	1.1	4
589	The improvement of treatment and prevention of non-alcoholic fatty liver disease progression against the background of metabolic disorders. <i>Modern Gastroenterology</i> , 2022, , 17-23.	0.1	0

#	ARTICLE	IF	CITATIONS
590	The role of intestinal microbiome in the progression of non-alcoholic fatty liver disease. <i>Modern Gastroenterology</i> , 2019, , 92-99.	0.1	0
591	Symbiotic microbes from the human gut. , 2023, , 533-549.		0
592	Protective Effects of <i>Lactobacillus gasseri</i> against High-Cholesterol Diet-Induced Fatty Liver and Regulation of Host Gene Expression Profiles. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2053.	1.8	1
593	Therapeutic efficacy of liraglutide versus metformin in modulating the gut microbiota for treating type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease. <i>Frontiers in Microbiology</i> , 0, 14, .	1.5	6
594	Colonic permeability is increased in non-cirrhotic patients with nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2023, 55, 614-621.	0.4	1
595	Beneficial effects of <i>Lactobacillus rhamnosus</i> hsrlyfm 1301 fermented milk on rats with nonalcoholic fatty liver disease. <i>Journal of Dairy Science</i> , 2023, 106, 1533-1548.	1.4	3
597	Emerging trends and hotspots in metabolic dysfunction-associated fatty liver disease (MAFLD) research from 2012 to 2021: A bibliometric analysis. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	7
598	The Role of the Gut Microbiome and Trimethylamine Oxide in Atherosclerosis and Age-Related Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2399.	1.8	5
599	Disturbance of lipid metabolism in germ-free mice transplanted with gut microbiota of DSS-induced colitis mice. <i>PLoS ONE</i> , 2023, 18, e0280850.	1.1	3
600	<i>Eucommia</i> Bark/Leaf Extract Improves Lipid Metabolism Disorders by Affecting Intestinal Microbiota and Microbiome-Host Interaction in HFD Mice. <i>Journal of Agricultural and Food Chemistry</i> , 2023, 71, 3297-3314.	2.4	3
601	Metabolic-associated fatty liver disease: pharmacological management. , 2023, , 319-341.		0
602	Noninvasive Tests Used in Risk Stratification of Patients with Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2023, 27, 373-395.	1.0	3
603	The Role Bariatric Surgery and Endobariatric Therapies in Nonalcoholic Steatohepatitis. <i>Clinics in Liver Disease</i> , 2023, 27, 413-427.	1.0	2
604	Metformin alleviates liver fibrosis in mice by enriching <i>Lactobacillus</i> sp. MF-1 in the gut microbiota. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2023, 1869, 166664.	1.8	2
605	Fructooligosaccharides attenuate non-alcoholic fatty liver disease by remodeling gut microbiota and association with lipid metabolism. <i>Biomedicine and Pharmacotherapy</i> , 2023, 159, 114300.	2.5	8
606	Sulforaphane Ameliorates Nonalcoholic Fatty Liver Disease Induced by High-Fat and High-Fructose Diet via LPS/TLR4 in the Gut-Liver Axis. <i>Nutrients</i> , 2023, 15, 743.	1.7	6
607	Antibiotic-Therapy-Induced Gut Dysbiosis Affecting Gut Microbiota-Brain Axis and Cognition: Restoration by Intake of Probiotics and Synbiotics. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3074.	1.8	32
608	Tocotrienol in the Management of Nonalcoholic Fatty Liver Disease: A Systematic Review. <i>Nutrients</i> , 2023, 15, 834.	1.7	1

#	ARTICLE	IF	CITATIONS
609	Functional foods and dietary supplements in the management of non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Frontiers in Nutrition</i> , 0, 10, .	1.6	3
610	Self-assembling polymer-based short chain fatty acid prodrugs ameliorate non-alcoholic steatohepatitis and liver fibrosis. <i>Biomaterials</i> , 2023, 295, 122047.	5.7	8
611	Protective Effects of Hydroxyphenyl Propionic Acids on Lipid Metabolism and Gut Microbiota in Mice Fed a High-Fat Diet. <i>Nutrients</i> , 2023, 15, 1043.	1.7	3
612	The Effects of Probiotics on Small Intestinal Microbiota Composition, Inflammatory Cytokines and Intestinal Permeability in Patients with Non-Alcoholic Fatty Liver Disease. <i>Biomedicines</i> , 2023, 11, 640.	1.4	14
613	Subgingival microbiome at different levels of cognition. <i>Journal of Oral Microbiology</i> , 2023, 15, .	1.2	1
614	Effect of Moderate to Severe Hepatic Steatosis on Vaccine Immunogenicity against Wild-Type and Mutant Virus and COVID-19 Infection among BNT162b2 Recipients. <i>Vaccines</i> , 2023, 11, 497.	2.1	1
615	Gut-Microbiota Dysbiosis in Stroke-Prone Spontaneously Hypertensive Rats with Diet-Induced Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4603.	1.8	1
616	Bifidobacterium-derived short-chain fatty acids and indole compounds attenuate nonalcoholic fatty liver disease by modulating gut-liver axis. <i>Frontiers in Microbiology</i> , 0, 14, .	1.5	12
617	Mini review: STING activation during non-alcoholic fatty liver disease. <i>Frontiers in Nutrition</i> , 0, 10, .	1.6	1
618	Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity. <i>BMC Microbiology</i> , 2023, 23, .	1.3	13
619	Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation. <i>Journal of Hepatology</i> , 2023, 79, 538-551.	1.8	27
620	Prolonged Antibiotic Exposure during Adolescence Dysregulates Liver Metabolism and Promotes Adiposity in Mice. <i>American Journal of Pathology</i> , 2023, 193, 796-812.	1.9	3
621	Multi-omics studies in interpreting the evolving standard model for immune functions. <i>Briefings in Functional Genomics</i> , 2024, 23, 75-81.	1.3	0
622	Integrated-gut-liver-on-a-chip platform as an in vitro human model of non-alcoholic fatty liver disease. <i>Communications Biology</i> , 2023, 6, .	2.0	14
623	The role of microbiome in the pathogenesis of oral-gut-liver axis between periodontitis and nonalcoholic fatty liver disease. <i>Journal of Dental Sciences</i> , 2023, 18, 972-975.	1.2	1
624	Intestinal permeability and its role in the pathogenesis of metabolic disorders (metabolic syndrome). Literature review. <i>Ukrainian Therapeutical Journal</i> , 2023, , 44-56.	0.0	0
625	Long-term Use of Proton Pump Inhibitors is Associated With An Increased Risk of Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2024, 58, 289-296.	1.1	0
626	Vitamin C and vitamin D3 alleviate metabolic-associated fatty liver disease by regulating the gut microbiota and bile acid metabolism via the gut-liver axis. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	3

#	ARTICLE	IF	CITATIONS
627	Fatty Liver Disease. , 2024, , 330-401.		1
628	Dietary cholesterol drives the development of nonalcoholic steatohepatitis by altering gut microbiota mediated bile acid metabolism in high-fat diet fed mice. Journal of Nutritional Biochemistry, 2023, 117, 109347.	1.9	4
629	Increased Risk of Young-Onset Digestive Tract Cancers Among Young Adults Age 20-39 Years With Nonalcoholic Fatty Liver Disease: A Nationwide Cohort Study. Journal of Clinical Oncology, 2023, 41, 3363-3373.	0.8	11
630	Probiotics as Potential Therapy in the Management of Non-Alcoholic Fatty Liver Disease (NAFLD). Fermentation, 2023, 9, 395.	1.4	0
631	Comparison between metabolic-associated fatty liver disease and nonalcoholic fatty liver disease: From nomenclature to clinical outcomes. World Journal of Hepatology, 0, 15, 477-496.	0.8	2
635	Phage therapy in gut microbiome. Progress in Molecular Biology and Translational Science, 2023, , .	0.9	0
663	Mechanisms Behind NAFLD: a System Genetics Perspective. Current Atherosclerosis Reports, 2023, 25, 869-878.	2.0	1
676	Non-alcoholic Fatty Liver Disease. , 2023, , 1-17.		0
681	Neurotensin modulation of inflammation: an update. Comparative Clinical Pathology, 0, , .	0.3	0
692	Gut liver brain axis in diseases: the implications for therapeutic interventions. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	3
706	Gut-brain communication mediates the impact of dietary lipids on cognitive capacity. Food and Function, 2024, 15, 1803-1824.	2.1	0
710	Non-alcoholic Fatty Liver Disease. , 2023, , 567-583.		0